EFFICACY PREDICTION METHOD OF ANTI-IL-6 RECEPTOR ANTIBODY THERAPY TO RHEUMATOID ARTHRITIS PATIENT

PROBLEM TO BE SOLVED: To provide a biomarker for predicting the efficacy of anti-IL-6 receptor antibody therapy in rheumatoid arthritis patients before the therapy is applied, and to provide a method for predicting the efficacy of anti-IL-6 receptor antibody therapy in a rheumatoid arthritis patient...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	SUZUKI YOSHIE, NAKAJIMA YASUSHI, KAGAMI SHINICHIRO, NAKAYAMA TOSHINORI, NONAKA KEN, IKEDA HIROSHI, OBARA OSAMU, MATOBA AKIRA
Format:	Patent
Sprache:	eng ; jpn
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR COMPOSITIONS THEREOF CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES CULTURE MEDIA ENZYMOLOGY INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PHYSICS PROCESSES OF PREPARING SUCH COMPOSITIONS PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS TESTING VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	PROBLEM TO BE SOLVED: To provide a biomarker for predicting the efficacy of anti-IL-6 receptor antibody therapy in rheumatoid arthritis patients before the therapy is applied, and to provide a method for predicting the efficacy of anti-IL-6 receptor antibody therapy in a rheumatoid arthritis patients using the biomarker.SOLUTION: The invention provides a method for predicting the efficacy of the therapy by the anti-IL-6 receptor antibody to rheumatoid arthritis comprising the steps of: measuring the expression level of at least one gene selected from the drag efficacy marker gene group consisting of MT1G, IFI6, MX2, and OASL in the peripheral blood monocyte sample isolated from a rheumatoid arthritis patients; and identifying the correlation between the expression level of the measured drug efficacy marker gene and the efficacy of the therapy by the anti-human IL-6 receptor antibody to rheumatoid arthritis. The invention also provides a diagnostic agent and diagnostic kit used for the method. 【課題】関節リウマチ患者における抗ＩＬ−６受容体抗体治療の有効性を、該治療を適用する以前に予測するためのバイオマーカーを提供し、該バイオマーカーを使用して、関節リウマチ患者における抗ＩＬ−６受容体抗体治療の有効性を予測する方法を提供すること。【解決手段】関節リウマチに対する抗ＩＬ−６受容体抗体による治療の有効性を予測するための方法であって、関節リウマチ患者から単離された末梢血単核球試料において、ＭＴ１Ｇ、ＩＦＩ６、ＭＸ２、およびＯＡＳＬからなる薬効マーカー遺伝子群から選択される少なくとも１つの遺伝子の発現レベルを測定すること、並びに測定した薬効マーカー遺伝子の発現レベルと、関節リウマチに対する抗ヒトＩＬ−６受容体抗体による治療の有効性とを相関付けることを含む方法、並びに該方法に使用する診断薬および診断用キットを提供する。【選択図】なし